Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has resolved to provide a payment guarantee of approximately KRW 332.9B for the real estate lease agreement of a US entity acquired through its wholly owned US subsidiary.
📊 [Key Disclosure Details & Financial Figures]
- Debtor: Human Genome Sciences Inc. (Acquired from GSK by Samsung Biologics America, Inc., a 100% subsidiary of Samsung Biologics)
- Creditor (Lessor): GI TC ROCKVILLE, LLC
- Guarantee Amount: KRW 332,876,599,672 (USD 221,962,125.54)
- Applied Exchange Rate: USD/KRW 1,499.70 (Initial base rate on disclosure date, March 20, 2026)
- Equity Capital: KRW 7,451,110,647,985 (Based on consolidated financial statements as of end-2025)
- Guarantee Amount to Equity Ratio: 4.47%
- Guarantee Period: March 31, 2026 – May 31, 2034
- Purpose & Subject Property: Payment guarantee for the lease agreement of the property located at 9911 Belward Campus Drive, Rockville, Maryland, USA, currently leased and used by Human Genome Sciences Inc.
- Board Resolution Date: March 20, 2026 (4 outside directors attended, 0 absent)
- Other Matters: The final guarantee amount is subject to change depending on future exchange rate fluctuations and lease execution details. Details regarding debtor financial statements were omitted as they were integrated into former parent company GSK’s financials.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Changes in Final Guarantee Amount Driven by Exchange Rates and Lease Execution
This guarantee amount was calculated using the exchange rate on the disclosure submission date (KRW 1,499.70 per USD), meaning the final guarantee figure may fluctuate according to future exchange rate movements and lease execution progress.
Tracking the actual changes in the finalized guarantee amount is crucial for accurately understanding the scale of the company’s financial contingent obligations.
Relevant progress and updates can be verified in upcoming periodic reports and relevant follow-up disclosures.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
